Abstract
Background: Schizophrenia is a lifelong illness with little recent progress in new pharmacologic treatments. Cloza-pine (CLZ) is the most effective antipsychotic drug for schizophrenia treatment. Yet, it remains underutilized since frequent blood draws are required to monitor white blood cell (WBC) counts. In addition, the evidence-based and recommended use of CLZ blood levels to guide treatment response are often underutilized by clinicians. Real-time monitoring of treatment efficacy and safety will enable personalized medicine and better utilization of CLZ. Labon-a-chip (LOC) biosensing devices are a promising solution and provide numerous advantages, such as small sample volume, ease of use, fast response, low cost, and high throughput. This could allow on-site testing with immediate results at the point-of-care, such as the pharmacy or physicians office. To date it is unknown if this technology would be accepted and utilized by clinicians and if CLZ detection could be done through a LOC.
Original language | English |
---|---|
Article number | M188 |
Pages (from-to) | S237-S238 |
Number of pages | 2 |
Journal | Neuropsychopharmacology |
Volume | 38 |
Issue number | S2 |
State | Published - Dec 2013 |
Keywords
- Clozapine
- Biosensor
- Blood levels
- Monitoring